Claims
- 1. An isolated polypeptide selected from the group consisting of:a) a polypeptide comprising a sequence of amino acid residues from amino acid residue 30 to amino acid residue 95 of SEQ ID NO:2; b) a polypeptide comprising a sequence of amino acid residues from amino acid residue 30 to amino acid residue 96 of SEQ ID NO:2; and c) a polypeptide comprising a sequence of amino acid residues from amino acid residue 30 to 97 of SEQ ID NO:2; d) a polypeptide comprising a sequence of amino acid residues from amino acid residue 30 to amino acid residue 98 of SEQ ID NO:2; e) a polypeptide comprising a sequence of amino acid residues from amino acid residue 98 to amino acid residue 243 of SEQ ID NO:2; f) a polypeptide comprising a sequence of amino acid residues from amino acid residue 99 to amino acid residue 243 of SEQ ID NO:2; and g) a polypeptide comprising a sequence of amino acid residues from amino acid residue 30 to amino acid residue 243 of SEQ ID NO:2.
- 2. An isolated polypeptide according to claim 1, covalently linked amino terminally or carboxy terminally to a moiety selected from the group consisting of affinity tags, toxins, radionucleotides, enzymes and fluorophores.
- 3. A pharmaceutical composition comprising a polypeptide according to claim 1, in combination with a pharmaceutically acceptable vehicle.
REFERENCE TO RELATED APPLICATIONS
This application is related to Provisional Application No. 60/056,983, filed on Aug. 26, 1997. Under 35 U.S.C. §119(e) (1), this application claims benefit of said Provisional Application.
Foreign Referenced Citations (1)
Number |
Date |
Country |
9639429 |
Dec 1996 |
WO |
Non-Patent Literature Citations (5)
Entry |
Maeda et al., Biochem. Biophys. Res. Comm. 221: 286-289, 1996. |
Scherer et al., J. Biol. Chem. 270:26746-26749, 1995. |
Sellar et al., Biochem. J. 274: 481-490, 1991. |
Gieser and Swaroop, Genomics 13: 873-876, 1992. |
Daniel, C. et al., Virology 202(540-549)1994. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/056983 |
Aug 1997 |
US |